2,941 reports of this reaction
14.7% of all METHOXY POLYETHYLENE GLYCOL EPOETIN BETA reports
#1 most reported adverse reaction
DRUG HYPERSENSITIVITY is the #1 most commonly reported adverse reaction for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA, manufactured by Vifor (International) Inc.. There are 2,941 FDA adverse event reports linking METHOXY POLYETHYLENE GLYCOL EPOETIN BETA to DRUG HYPERSENSITIVITY. This represents approximately 14.7% of all 19,964 adverse event reports for this drug.
Patients taking METHOXY POLYETHYLENE GLYCOL EPOETIN BETA who experience drug hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG HYPERSENSITIVITY is a frequently reported adverse event for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA, accounting for a significant proportion of all reports.
In addition to drug hypersensitivity, the following adverse reactions have been reported for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA:
The following drugs have also been linked to drug hypersensitivity in FDA adverse event reports:
DRUG HYPERSENSITIVITY has been reported as an adverse event in 2,941 FDA reports for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG HYPERSENSITIVITY accounts for approximately 14.7% of all adverse event reports for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA, making it one of the most commonly reported side effect.
If you experience drug hypersensitivity while taking METHOXY POLYETHYLENE GLYCOL EPOETIN BETA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.